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Introduction: We previously reported the prognostic significance of 
the lung adenocarcinoma immune microenvironment. In this study, 
we preformed comprehensive analysis of immune markers and their 
associations with prognosis in patients with lung squamous cell 
carcinoma.
Methods: We reviewed surgically resected, solitary lung squamous 
cell carcinoma patients (n = 485; 1999–2009) who were randomly 
split into a training cohort (n = 331) and validation cohort (n = 154). 
We constructed tissue microarrays and performed immunostaining 
for CD3, CD45RO, CD8, CD4, FoxP3, CD20, CD68, CXCL12, 
CXCR4, CCR7, interleukin-7 receptor, and interleukin-12 receptor 
β2. Overall survival (OS) was analyzed using the log-rank test and 
the Cox proportional hazards model.
Results: Analysis of single immune cell infiltration revealed that high 
tumor-infiltrating CD10+ neutrophils were associated with worse 
prognoses in the training cohort (p = 0.021). Analysis of biologically 
relevant immune cell combinations identified that patients with high 
CD10+ neutrophil and low CD20+ lymphocyte had a significantly 
worse OS (5-year OS, 42%) than those with other combinations of 
CD10 and CD20 (5-year OS, 62%; p < 0.001); this was confirmed 
in the validation cohort (p = 0.032). For the multivariate analysis, 
high CD10/low CD20 immune cell infiltration was an independent 
predictor of OS in both the training cohort (hazard ratio = 1.61, 
p = 0.006) and the validation cohort (hazard ratio = 1.75; p = 0.043).
Conclusion: High CD10+/low CD20+ immune cell infiltration 
ratio is a significant prognostic factor of lung squamous cell carci-
noma. Immunomodulatory therapy of tumor-specific neutrophil and 
B-lymphocyte responses may have applicability in the treatment of 
lung squamous cell carcinoma.
Key Words: Tumor infiltrating lymphocytes, Immune response, 
Non–small-cell lung cancer, Survival.
(J Thorac Oncol. 2015;10: 1301–1310)
Lung cancer is the leading cause of cancer-related mortal-ity worldwide for men and the second leading cause for 
women.1,2 Two major histologic types of lung cancers are 
squamous cell carcinoma and adenocarcinoma. Although 
squamous cell carcinoma currently comprises a higher pro-
portion of diagnosed lung cancers in males,3 the rate of squa-
mous cell carcinoma has been increasing among females and 
declining among males in North America.4
To date, tumor, node, metastasis (TNM) stage is the 
most reliable prognostic predictor and dictates therapeutic 
decisions for solid malignancies, including non–small-cell 
lung cancer (NSCLC).5 Prognostic value of tumor-infiltrating 
immune cells has been proven in solid malignancies, which is 
influenced by type, density, and location of immune cells.6–12 
Tumor-infiltrating immune cells have also been identified as a 
prognostic factor in NSCLC, but these reports included het-
erogeneous cohorts in tumor histologic types.13–18
Recently, by using a homogeneous large cohort of 
stage I lung adenocarcinoma patients, we have identified high 
tumor-infiltrating FoxP3/CD3 lymphocytes ratio in tumor-
related stroma, overexpression of interleukin-7 receptor 
(IL-7R), and loss of IL-12 receptor β2 (IL-12Rβ2) expres-
sion in tumor cells as independent prognostic factors of 
stage I lung adenocarcinoma.19 However, prognostic util-
ity of immune markers, such as tumor-infiltrating immune 
cell and cytokine (receptors) expression, remains unknown 
in lung squamous cell carcinoma. In this study, we investi-
gated whether immune markers, including type and density 
of tumor-infiltrating immune cells and tumoral cytokine 
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(receptor) expression, correlated with clinical outcomes in a 
uniform cohort of patients with resected lung squamous cell 
carcinoma. In addition, we also evaluated the peripheral blood 
immune markers and inflammation scores on hematoxylin and 
eosin (H&E)–stained slides.
PATIENTS AND METHODS
Patients
This retrospective study was approved by the Institutional 
Review Board of Memorial Sloan Kettering Cancer Center. 
We reviewed patients with therapy-naïve, solitary lung squa-
mous cell carcinoma who had undergone surgical resection at 
Memorial Sloan Kettering Cancer Center between 1999 and 
2009; 485 of those patients had tumor slides that were avail-
able for histologic evaluation. Clinical data were collected 
from the prospectively maintained Thoracic Surgery Service 
Lung Carcinoma Database, and disease stage was assigned 
based on the 7th edition of the American Joint Committee on 
Cancer TNM Staging Manual.20
Preoperative peripheral blood cell count test results—
which included total white blood cell, neutrophil, and lympho-
cyte counts—were available for 466 patients. The neutrophil/
lymphocyte ratio (NLR) was defined as absolute neutrophil 
count divided by absolute lymphocyte count, as reported 
previously.21–29
Histologic Evaluation
All available H&E–stained slides were reviewed by two 
pathologists (K.K. and W.D.T.), who were blinded to patient 
clinical outcomes, using an Olympus BX51 microscope 
(Olympus Optical, Tokyo, Japan) with a standard 22-mm 
diameter eyepiece.
With regard to histologic inflammation scores based on the 
H&E–stained slides,30 acute inflammation (neutrophil infiltra-
tion), chronic inflammation (lymphocyte and plasma cell infil-
tration), and lymph follicle (any lymphoid nodule) count were 
tabulated for each case. Percentage of acute inflammation area 
was recorded using three high-power fields at ×400 magnifica-
tion with the most severe inflammatory reaction; this was done 
after all tumor slides were scanned using intermediate-power 
fields at ×100 magnification. Percentage of chronic inflamma-
tion area and lymph follicle count were recorded using three 
low-power fields at ×40 magnification of the region with the 
most severe inflammatory reaction, after reviewing all tumor 
slides at scanning magnification. In addition, pleural invasion, 
which was classified as absent (PL0) or present (PL1, PL2, and 
PL3),20 and lymphovascular invasion were investigated.
Tissue Microarray
In our recent publications on lung adenocarcinoma, 
both tumoral and stromal cores were used for tissue microar-
rays.19 However, on review of H&E–stained slides, we evalu-
ated only tumoral cores because the tumoral component was 
intermingled with the stromal component at a greater level in 
squamous cell carcinoma than in adenocarcinoma; also, it was 
difficult to construct tissue microarrays composed of purely 
tumoral or stromal cores.
Formalin-fixed, paraffin-embedded tumor specimens 
(n = 451) were used for tissue microarray construction. We 
marked three representative tumor areas with the most severe 
inflammatory reaction on H&E–stained slides, and by using 
an automated tissue arrayer ATA-27 (Beecher Instruments, 
Sun Prairie, WI), we arrayed cylindrical, 0.6-mm tissue cores 
from corresponding paraffin blocks into recipient blocks; this 
resulted in five tissue microarray blocks. In total, there were 
447 available cases with adequate cores for immunohisto-
chemical analysis.
Immunohistochemistry and Scoring  
of Immune Markers
Briefly, 4-μm sections from the tissue microarray blocks 
were deparaffinized in xylene and dehydrated in graded alco-
hols. Standard avidin–biotin–peroxidase complex technique 
was used to immunohistochemically stain the immune markers 
(CD3, CD45RO, CD8, CD4, FoxP3, CD20, CD68, CXCL12, 
CXCR4, CCR7, IL-7R, and IL-12Rβ2), as we previously 
reported.19 In addition, the anti-CD10 antibody (56C6, Vector 
Laboratories, Burlingame, CA; diluted at 1:50) was used as a 
neutrophil granulocyte marker.31,32 Sections were stained using 
a Ventana Discovery XT Automated Immunohistochemical 
Stainer (Ventana Medical Systems, Tucson, AZ), according 
to the manufacturer’s guidelines. Diaminobenzidine was used 
as the chromogen, and hematoxylin was used as the nuclear 
counterstain. Positive control tissues were stained in parallel 
with the study cases.
Under high-power field at ×200 magnification, the 
amount of tumor-infiltrating immune cells that were positive 
for each marker was counted in each core. The score for each 
patient was determined by averaging the number of positive 
cells for all cores that were available for analysis.19 In addition, 
the ratio of T-lymphocyte subtypes (CD45RO, CD8, CD4, and 
FoxP3) to pan T cells (CD3) was calculated.
Scoring of cytokines and cytokine receptors was based 
on the distribution and intensity of staining.19,33 Distribution 
was scored as 0 (0%), 1 (1%–50%), and 2 (>50%) to indi-
cate percentage of positive cells in each core. Intensity of 
the staining was scored as 0 (no expression), 1 (mild expres-
sion), 2 (intermediate expression), and 3 (strong expression). 
Distribution and intensity scores were summed into a total 
score (0–5), and the average score of all available cores was 
considered the score for each patient.
Statistical Analysis
The entire cohort was randomly split into a training 
cohort (n = 331) and a validation cohort (n = 154) at a 2:1 
ratio, and they were stratified by temporal intervals of surgery 
and pathologic stage. Associations between variables were 
analyzed using Fisher’s exact test (for categorical variables) 
and the Wilcoxon test (for continuous variables).
We investigated two end points: overall survival (OS) and 
cumulative incidence of recurrence (CIR). OS was estimated 
using the Kaplan–Meier method, and associations between 
factors and OS were analyzed using the log-rank test and 
stratified by pathologic stage. Using the cutoffs from our pre-
vious studies, immune cells that were positive for each marker 
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were dichotomized into low and high groups.19,32 Peripheral 
blood cell count, histologic inflammation score, ratio of 
T-lymphocyte subtypes (CD45RO, CD8, CD4, and FoxP3) to 
pan T cells (CD3), and tumoral cytokine (receptor) expression 
were dichotomized using the optimal cut-point method, and p 
values were adjusted for optimal search.34 OS was defined as 
time from surgery to death or last follow-up. A multivariate 
analysis was performed using the Cox proportional hazards 
regression model. Multivariate models were built to include 
all significant factors on univariate analyses. Any associations 
between pathologic factors were checked, and if any strong 
associations were discovered, only one factor at any given 
time was included in the model. Associations between fac-
tors and risk of recurrence were evaluated using competing 
risks methods.35,36 CIR was estimated using a cumulative inci-
dence function that accounted for death without recurrence as 
a competing event. Patients were censored if they were alive 
without a documented recurrence at most recent follow-up. 
Differences in CIR between groups were assessed using the 
gray method (univariate nonparametric analysis).37
All statistical tests were two sided, and 5% was set as the 
level of significance. Statistical analyses were performed using 
R (version 3.0.1; R Development Core Team, Vienna, Austria) 
with the “maxstat,” “survival,” and “cmprsk” packages.
RESULTS
Patient Clinicopathologic Characteristics 
and Their Associations with OS
Clinicopathologic characteristics of patient in the train-
ing cohort are summarized in Table 1. Median age of patients 
was 72 years (range, 39–88 years), and most had pathologic 
TABLE 1.  Associations between Clinicopathologic Characteristics and Overall Survival in the Training Cohort
Variables n (%) 5-yr OS (%) p HR 95% CI
Age (yr)
  ≤65 85 (26) 63 0.050 Ref.
  >65 246 (74) 56 1.44 1.00–2.07
Sex
  Female 134 (40) 65 0.066 Ref.
  Male 197 (60) 53 1.32 0.98–1.78
Smoking pack-year
  ≤90 268 (81) 62 0.004 Ref.
  >90 63 (19) 41 1.64 1.17–2.31
Surgery
  Lobectomy 278 (84) 59 0.15 Ref.
  Limited resection 53 (16) 52 1.32 0.91–1.93
Adjuvant therapy
  No 273 (82) 58 0.90 Ref.
  Yes 58 (18) 58 1.03 0.69–1.54
T classification
  T1 146 (44) 67 <0.001 Ref.
  T2 142 (43) 54 1.26 0.92–1.72
  T3 + T4 43 (13) 39 2.23 1.45–3.43
N classification
  N0 239 (72) 61 0.020 Ref.
  N1 58 (18) 51 1.38 0.95–2.00
  N2 34 (10) 45 1.76 1.12–2.74
Pathologic stage
  Stage I 190 (57) 65 <0.001 Ref.
  Stage II 93 (28) 52 1.43 1.03–1.98
  Stage III 48 (15) 39 2.30 1.55–3.43
Pleural invasion
  Absent (PL0) 280 (85) 60 0.010 Ref.
  Present (PL123) 51 (15) 45 1.49 1.09–2.05
Lymphovascular invasion
  Absent 104 (31) 69 0.013 Ref.
  Present 227 (69) 52 1.62 1.12–2.33
Significant p values are shown in bold.
CI, confidence interval; HR, hazard ratio; OS, overall survival.
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stage I disease (57%), followed by stage II disease (28%) and 
stage III disease (15%). With regard to surgical procedure, 
84% had undergone lobectomy and 16% had undergone lim-
ited resection. Eighteen percent of patients received adjuvant 
therapy. There were no significant differences between patient 
clinicopathologic characteristics identified between the train-
ing and the validation cohorts.
In the training cohort, 30% of patients (n = 99) expe-
rienced a recurrence and 57% (n = 188) died from any cause 
during the follow-up period (median, 49 months; range, 
0.1–156 months). In the validation cohort, 26% of patients 
(n = 40) experienced a recurrence and 60% (n = 93) died from 
any cause during the follow-up period (median, 54 months; 
range, 0.1 to 152 months).
The associations between patient clinicopathologic 
characteristics and OS in the training cohort are summarized 
in Table 1. With regard to pathologic stage, 5-year OS was the 
worst for patients with stage III disease, followed by patients 
with stage II disease and stage I disease (5-year OS, 39%, 
52%, and 65%, respectively; p < 0.001). On univariate OS 
analysis, history of heavier smoking (>90 smoking pack-year; 
p = 0.004), pleural invasion (p = 0.010), and lymphovascular 
invasion (p = 0.013) were associated with worse OS.
Associations between White Blood Cell 
Counts in Peripheral Blood and OS
In the training cohort, low percentage of lymphocyte 
(p = 0.005) and high NLR (p = 0.001) were associated with 
worse OS (Table 2). However, these findings were not repro-
duced in the validation cohort.
Associations between Histologic 
Inflammation Scores and OS
In the training cohort, high degree of acute inflamma-
tion (p = 0.013) and high lymph follicle count (p = 0.041) in 
tumors were associated with worse OS (Table 2). However, 
these findings were not reproduced in the validation cohort.
TABLE 2.  Associations between Peripheral Blood Cell Count Test or Histologic Inflammation Scores and Overall Survival in the 
Training Cohort
Variables n (%) 5-yr OS (%) pa HR 95% CI
Complete blood count
  White blood cell (n)
   Low (≤7) 125 (39) 62 0.32 Ref.
   High (>7) 194 (61) 55 1.17 0.86–1.59
  Neutrophil (%)
   Low (≤77) 264 (83) 60 0.26 Ref.
   High (>77) 55 (17) 45 1.24 0.85–1.79
  Neutrophil (n)
   Low (≤4) 84 (26) 57 0.92 Ref.
   High (>4) 235 (74) 58 1.02 0.72–1.43
  Lymphocyte (%)
   Low (≤15) 71 (22) 38 0.005 Ref.
   High (>15) 248 (78) 63 0.62 0.45–0.87
  Lymphocyte (n)
   Low (≤2) 257 (81) 55 0.26 Ref.
   High (>2) 62 (19) 69 0.80 0.54–1.18
  Neutrophil/lymphocyte ratio
   Low (≤5.5) 266 (83) 62 0.001 Ref.
   High (>5.5) 53 (17) 34 1.82 1.26–2.62
Histologic inflammation scores
  Acute inflammation (%)
   Low (<5) 212 (64) 60 0.013 Ref.
   High (≥5) 119 (36) 53 1.46 1.08–1.97
  Chronic inflammation (%)
   Low (<10) 196 (59) 59 0.71 Ref.
   High (≥10) 135 (41) 56 1.06 0.79–1.42
  Lymph follicles (n)
   Low (<5) 188 (57) 62 0.041 Ref.
   High (≥5) 143 (43) 52 1.35 1.01–1.81
Significant p values are shown in bold.
ap values adjusting for pathologic stage.
CI, confidence interval; HR, hazard ratio; OS, overall survival.
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Associations between Immunohistochemical 
Immune Markers and OS or CIR
In the training cohort, OS of patients with high tumor-
infiltrating CD10+ neutrophils was significantly worse 
(n = 111; 5-year OS, 52%) than those with low tumor- 
infiltrating CD10+ neutrophils (n = 191; 5-year OS, 60%; 
p = 0.021; Table 3); however, this finding was not confirmed 
in the validation cohort (5-year OS, 55% [high CD10] versus 
64% [low CD10]; p = 0.37). The other single immune markers 
were not associated with OS.
We then analyzed prognostic value by the biologically rel-
evant combinations of two types of tumor-infiltrating immune 
cells and identified the combination of tumor-infiltrating CD10+ 
neutrophils and CD20+ lymphocytes as a powerful prognostic 
factor. Figure 1 represents CD10+ neutrophil and CD20+ lym-
phocytes infiltrating tumors. The OS of patients with high CD10+ 
neutrophil and low CD20+ lymphocyte infiltration (5-year OS, 
42%) was significantly worse compared with those with low 
CD10/low CD20 (5-year OS, 62%; p = 0.001; hazard ratio 
[HR] = 0.55; 95% confidence interval [CI] = 0.38–0.79), low 
CD10/high CD20 (5-year OS, 55%; p = 0.026; HR = 0.58; 
95% CI = 0.36–0.94), and high CD10/high CD20 (5-year OS, 
70%; p = 0.043; HR = 0.60; 95% CI = 0.36–0.98; Fig. 2A). 
Based on this observation, CD10/CD20 risk index was estab-
lished as a strong predictor of OS—“high-risk” for high CD10/
low CD20 and “low risk” for low CD10/low CD20, low CD10/
high CD20, and high CD10/high CD20. Using this risk index in 
the training cohort, OS of patients with high CD10/CD20 risk 
index was significantly worse (n = 72; 5-year OS, 42%) than 
those with low risk index (n = 228; 5-year OS, 62%; p < 0.001; 
HR = 0.56; 95% CI = 0.4–0.78; Fig. 2B). This finding was con-
firmed in the validation cohort. The OS of patients with high 
CD10+ neutrophil and low CD20+ lymphocyte infiltration (5-year 
OS, 46%) was relatively worse compared with those with low 
CD10/low CD20 (5-year OS, 58%; p = 0.069; HR = 0.61; 95% 
CI = 0.36–1.04), low CD10/high CD20 (5-year OS, 84%; p = 0.10; 
HR = 0.55; 95% CI = 0.27–1.13), and high CD10/high CD20 
(5-year OS, 71%; p = 0.092; HR = 0.52; 95% CI = 0.24–1.11; 
Fig. 3A). OS of patients with high CD10/CD20 risk index was 
significantly worse (n = 30; 5-year OS, 46%) than those with low-
risk index (n = 112; 5-year OS, 66%; p = 0.032; HR = 0.58; 95% 
 CI = 0.35–0.96; Fig. 3B).
For the multivariate analysis of OS, adjusting for patient 
age, sex, smoking status (pack-year), surgical procedure, patho-
logic stage, and lymphovascular invasion in the training cohort 
(Table 4), CD10/CD20 risk index was an independent predictor 
of OS (high risk versus low risk; HR = 1.61, p = 0.006). This 
finding was reproduced in the validation cohort (HR = 1.75; 
p = 0.043; Table 4). Among the other variables, only pathologic 
stage (stage III versus stage I) was confirmed as an independent 
prognostic factor in both the training (HR = 2.15; p = 0.001) 
and the validation cohorts (HR = 2.20; p = 0.040).
Next, we analyzed the correlation between CD10/CD20 
risk index and risk of recurrence in stage I patients. We deter-
mined that CD10/CD20 risk index was not associated with 
risk of recurrence (5-year CIR, 23% for high-risk index versus 
22% for low-risk index; p = 0.72).
DISCUSSION
In this study, by using two independent cohorts (training 
and validation) of patients with resected lung squamous cell 
carcinoma, we performed comprehensive analyses of immune 
factors such as NLR (based on the preoperative peripheral 
blood cell count), histologic immune scores (based on the 
H&E–stained slides), and immunohistochemical immune 
markers (based on the tissue microarray method) that included 
tumor-infiltrating immune cells and tumoral cytokine (recep-
tor) expressions. We identified the tumor-infiltrating CD10/
CD20 immune cell risk index (coincidence of high CD10+ 
neutrophil infiltration and low CD20+ B-lymphocyte infiltra-
tion in tumors) as a significant prognostic factor for OS that is 
independent of pathologic TNM stage.
With regard to type of tumor-infiltrating lympho-
cyte evaluated by immunohistochemistry, we have recently 
reported that high FoxP3 to CD3+ tumor-infiltrating lympho-
cyte ratio in tumor-related stroma was an independent prog-
nostic factor for patients with stage I lung adenocarcinoma.19 
In addition, previous studies by others have demonstrated 
that CD4+ or CD8+ tumor-infiltrating lymphocytes, as well as 
coincidence of CD4+ and CD8+ lymphocytes, were favorable 
prognostic factors for NSCLC.13,15,16 However, in our current 
study of lung squamous cell carcinoma, no single type of 
tumor-infiltrating lymphocytes nor any combination of tumor-
infiltrating lymphocytes (including combinations of FoxP3/
CD3 or CD4/CD8) were significantly associated with patient 
clinical outcomes.
Neutrophil count in pretreatment peripheral blood cell 
count has been identified as an independent prognostic fac-
tor using large cohorts of patients with advanced NSCLC.38,39 
Moreover, recent studies have reported increased NLR in 
preoperative or pretreatment peripheral blood cell count as a 
poor prognostic factor in various solid cancers,21–26 including 
NSCLC.27–29 Our findings, which are based on a large cohort 
of patients with resected lung squamous cell carcinoma, were 
compatible with the previous studies. OS of patients with 
high NLR was much lower than OS of those with low NLR 
(5-year OS, 34% versus 62%), and OS of patients with low 
lymphocyte percentage was much lower than those with high 
lymphocyte percentage (5-year OS, 38% versus 63%) in the 
training cohort. Because peripheral blood testing is inexpen-
sive, reproducible, preoperatively measurable, and widely 
available in clinical practice at different institutions, evalua-
tion of NLR may have potentially valuable implications as a 
clinical biomarker—with regard to preoperative (e.g., surgi-
cal procedures and neoadjuvant therapy) and postoperative 
decision-making (e.g., adjuvant therapy)—for improvement 
of patient clinical outcomes. This warrants further investiga-
tion based on the large external cohorts of patients with lung 
squamous cell carcinoma.
The tumor immune microenvironment can be directly 
evaluated more effectively using H&E–stained slides from 
resected tumors. In a previous study, an increased level of 
tumor-infiltrating lymphocytes correlated with improved 
recurrence-free survival in patients with early stage NSCLC.40 
In our study using H&E–stained slides of resected lung squa-
mous cell carcinomas, chronic inflammation (tumor-infiltrating 
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TABLE 3.  Associations between Tumor-Infiltrating Immune Cell Subtypes and Overall Survival in the Training Cohort
Variables n (%) 5-yr OS (%) pa HR 95% CI
No. of positive cell count
  CD3
   Low (<50) 91 (30) 61 0.38 Ref.
   High (≥50) 212 (70) 55 1.16 0.83–1.61
  CD45RO
   Low (<50) 160 (52) 58 0.44 Ref.
   High (≥50) 146 (48) 56 1.13 0.84–1.51
  CD8
   Low (<50) 165 (54) 59 0.52 Ref.
   High (≥50) 141 (46) 55 1.10 0.82–1.48
  CD4
   Low (<20) 146 (48) 58 0.42 Ref.
   High (≥20) 160 (52) 57 1.13 0.84–1.53
  FoxP3
   Low (<20) 135 (44) 59 0.29 Ref.
   High (≥20) 171 (56) 55 1.18 0.87–1.60
  CD20
   Low (<20) 216 (71) 56 0.65 Ref.
   High (≥20) 87 (29) 62 0.92 0.66–1.29
  CD68
   Low (<50) 73 (24) 53 0.23 Ref.
   High (≥50) 230 (76) 59 0.81 0.58–1.14
  CD10
   Low (<10) 191 (63) 60 0.021 Ref.
   High (≥10) 111 (37) 52 1.43 1.06–1.94
Ratio to CD3+ cells (%)
  CD45RO
   Low (≤19) 31 (10) 78 0.079 Ref.
   High (>19) 272 (90) 55 1.72 0.93–3.17
  CD8
   Low (≤31) 62 (20) 65 0.067 Ref.
   High (>31) 241 (80) 55 1.42 0.97–2.07
  CD4
   Low (≤4) 48 (16) 69 0.15 Ref.
   High (>4) 255 (84) 55 1.39 0.88–2.20
  FoxP3
   Low (0) 247 (82) 55 0.32 Ref.
   High (>0) 56 (18) 66 0.82 0.55–1.21
Tumoral cytokine (receptor)
  CXCL12
   Low (≤4) 180 (59) 59 0.22 Ref.
   High (>4) 123 (41) 54 1.21 0.89–1.63
  CXCR4
   Low (≤4) 231 (76) 56 0.52 Ref.
   High (>4) 72 (24) 60 0.88 0.61–1.29
  CCR7
   Low (≤4) 114 (38) 51 0.21 Ref.
   High (>4) 190 (63) 61 0.82 0.61–1.12
  IL-7R
   Low (≤4) 143 (47) 58 0.34 Ref.
   High (>4) 163 (53) 56 0.86 0.64–1.16
  IL-12Rβ2
   Low (≤2) 49 (16) 62 0.26 Ref.
   High (>2) 255 (84) 56 1.27 0.84–1.94
Significant p values are shown in bold. 
ap values adjusting for pathologic stage.
CI, confidence interval; HR, hazard ratio; IL, interleukin; OS, overall survival.
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lymphocytes and plasma cells) in tumors did not correlate with 
prognosis, whereas acute inflammation (total tumor- infiltrating 
neutrophil) was associated with poor prognoses in the training 
cohort. This suggests that tumoral acute inflammation may play 
a more important role than chronic inflammation in tumor cell 
progression in lung squamous cell carcinoma.
Tumor-associated neutrophils (TANs) play an impor-
tant role in tumor biology. Neutrophils can promote tumor 
progression by activating angiogenesis41,42 and tumor metas-
tasis by facilitating tumor cell transendothelial migration.43 
Conversely, neutrophils can also suppress tumor progression 
by means of direct tumor cytotoxicity.44 However, prognostic 
utility of TANs remains unknown in lung cancers. We iden-
tified that tumor-related neutrophils have unfavorable prog-
nostic value in lung squamous cell carcinoma on the basis 
of three different aspects: (1) NLR measured by peripheral 
blood cell count; (2) tumoral acute inflammation (total neu-
trophil infiltration) evaluated by H&E–stained slides; and 
(3) tumor-infiltrating neutrophil (especially NLR) analyzed 
by immunohistochemistry. Recently, TANs have been clas-
sified into two different phenotypes—antitumorigenic (N1), 
induced by interferon-β, and protumorigenic type (N2), driven 
High CD10 Low CD20A
Low CD10 High CD20B
FIGURE 1.  CD10+ neutrophil and 
CD20+ lymphocyte infiltration in 
tumors. A, Tumor with high CD10+ 
neutrophil infiltration and low CD20+ 
lymphocyte infiltration. B, Tumor 
with low CD10+ neutrophil infiltra-
tion and high CD20+ lymphocyte 
infiltration.
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FIGURE 2.  Overall survival (OS) of combination 
of CD10+ neutrophil and CD20+ lymphocyte infil-
tration in the training cohort. A, OS of patients 
with high CD10+ neutrophil and low CD20+ 
lymphocyte infiltration (5-year OS, 42%) was 
significantly worse compared with those with  
low CD10/low CD20 (5-year OS, 62%;  
p = 0.001; hazard ratio [HR] = 0.55; 95% confi-
dence interval [CI] = 0.38–0.79), low CD10/high 
CD20 (5-year OS, 55%; p = 0.026; HR = 0.58; 
95% CI = 0.36–0.94), and high CD10/high CD20 
(5-year OS, 70%; p = 0.043; HR = 0.60; 95%  
CI = 0.36–0.98). B, OS of patients with high 
CD10/CD20 risk index was significantly worse  
(n = 72; 5-year OS, 42%) than those with low-
risk index (n = 228; 5-year OS, 62%; P < 0.001; 
HR = 0.56; 95% CI = 0.4–0.78).
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by transforming growth factor (TgF)-β.45,46 Interestingly, 
Eruslanov et al.47 demonstrated that in early-stage lung can-
cer, TANs were not immunosuppressive, but rather stimulate 
T-cell responses. Mishalian et al.48 reported that TANs had 
more cytotoxic effects on tumor cells in early-stage tumor 
development, whereas they acquired a more protumorigenic 
phenotype at later stages, thereby suggesting that TANs dis-
play different functions in different tumor microenvironments. 
There is no widely accepted immunohistochemical marker for 
detecting TAN phenotypes (N1 or N2). As a possible marker 
for N2 phenotype, TAN, tumor-infiltrating CD66b+ neutrophil, 
when referring to a specific activated subtype, was described 
as a poor prognostic immune factor of NSCLC, renal cell car-
cinoma, melanoma, and head and neck squamous cell carci-
noma.49–52 In addition, tumor-infiltrating CD10+ (cell surface 
zinc-dependent metalloprotease) neutrophil was reported to 
be a poor prognostic factor in patients with colorectal can-
cer and was associated with tumoral TgF-β expression. This 
suggests that CD10+ neutrophils may represent the N2 TAN 
phenotype that is activated by tumor cell–producing TgF-β.31 
Similarly, in our study, OS of patients with high CD10+ tumor-
infiltrating neutrophils was lower than those with low CD10+ 
neutrophils in both independent cohorts (5-year OS, 52% ver-
sus 60% for training cohort; 55% versus 64% for validation 
cohort).
The interaction between neutrophils and lymphocytes 
plays an important role in the tumor immune microenviron-
ment and nontumoral inflammatory process. Antitumorigenic 
TANs (N1) may increase activation of CD8+ cytotoxic 
T cells, whereas protumorigenic type TANs (N2) may inhibit 
cytotoxic response of CD8+ T cells; this allows tumor cells 
to escape immune surveillance.45 Moreover, the tumor-infil-
trating neutrophil to lymphocyte (CD8+ T cell) ratio has been 
recently reported as an independent poor prognostic factor in 
patients with NSCLC.49 In our study, we have demonstrated 
that the tumor-infiltrating neutrophil (CD10+ immune cells) 
to lymphocyte ratio (CD20+ B cell) is an independent prog-
nostic factor in patients with lung squamous cell carcinoma. 
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FIGURE 3.  Overall survival (OS) of combina-
tion of CD10+ neutrophil and CD20+ lymphocyte 
infiltration in the validation cohort. A, OS of 
patients with high CD10+ neutrophil and low 
CD20+ lymphocyte infiltration (5-year OS, 46%) 
was relatively worse compared with those with 
low CD10/low CD20 (5-year OS, 58%;  
p = 0.069; hazard ratio [HR] = 0.61; 95% confi-
dence interval [CI] = 0.36–1.04), low CD10/high 
CD20 (5-year OS, 84%; p = 0.10; HR = 0.55; 
95% CI = 0.27–1.13), and high CD10/high CD20 
(5-year OS, 71%; p = 0.092; HR = 0.52; 95%  
CI = 0.24–1.11). B, OS of patients with high 
CD10/CD20 risk index was significantly worse  
(n = 30; 5-year OS, 46%) than those with low-risk 
index (n = 112; 5-year OS, 66%; p = 0.032;  
HR = 0.58; 95% CI = 0.35–0.96).
TABLE 4.  Multivariate Analysis of Overall Survival
Variables
Training Cohort Validation Cohort
HR 95% CI p HR 95% CI p
Age, yr (>65 vs. ≤65) 1.29 0.87–1.91 0.20 2.51 1.36–4.64 0.003
Sex (males vs. females) 1.24 0.89–1.71 0.20 1.43 0.88–2.31 0.15
Smoking pack-year (>90 vs. ≤90) 1.46 1.00–2.14 0.048 0.84 0.45–1.55 0.57
Surgery (limited resection vs. 
lobectomy)
1.42 0.94–2.15 0.096 1.15 0.58–2.26 0.69
Pathologic stage
  Stage II vs. stage I 1.43 0.98–2.10 0.064 1.19 0.67–2.10 0.56
  Stage III vs. stage I 2.15 1.35–3.43 0.001 2.20 1.04–4.66 0.040
Lymphovascular invasion (present 
vs. absent)
1.06 0.75–1.50 0.73 2.14 1.21–3.77 0.009
CD10/CD20 risk index (high risk vs. 
low risk)
1.61 1.15–2.27 0.006 1.75 1.02–3.01 0.043
Significant p values are shown in bold.
CI, confidence interval; HR, hazard ratio.
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The biological interaction of TANs with CD20+ B cells in the 
tumor immune microenvironment is unclear; however, it was 
demonstrated that B cells inhibit neutrophil migration and, in 
contrast, B-cell deficiency leads to increased infiltration of 
neutrophil in the nontumoral inflammatory process.53,54 This 
suggests that B cells—especially regulatory B cells—have 
a suppressive effect on neutrophil inflammatory response. 
Therefore, we speculate that increased infiltration of B cells 
may suppress TANs, whereas decreased infiltration of B cells 
may upregulate TANs (possible N2 phonotype neutrophils) in 
the tumor immune microenvironment. This will, in turn, lead 
to tumor progression and poor clinical outcomes in lung squa-
mous cell carcinoma.
In conclusion, in this first large-scale study of the 
tumor immune microenvironment of patients with resected 
lung squamous cell carcinoma, we have identified prognostic 
immune markers. CD10/CD20 risk index (CD10+ neutrophil 
infiltration to CD20+ B lymphocytes ratio) was an indepen-
dent prognostic factor using two independent cohorts. More 
importantly, this finding may provide a crucial foundation for 
future investigations into immunomodulatory therapies for 
lung squamous cell carcinoma.
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